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Allogeneic hematopoietic cell transplantation (HCT) is used to treat hematologic disorders and 
malignancies; however, half of the transplant recipients develop chronic graft-versus-host disease 
(GVHD). Chronic GVHD is an immune disorder in which the transplanted donor T cells recognize 
transplant recipient cells as foreign and kill them, including those in the skin, mouth, eyes, liver, 
lungs, and other organs. Chronic GVHD is treated with immunosuppressive drugs to dampen the 
attack on transplant recipient cells. Sclerosis is a distinct clinical phenotype of chronic GVHD, and is 
associated with severe morbidity and disability among transplant survivors. Sclerosis begins in 
superficial layers of the skin and extends to deeper layers, developing from skin thickening 
(cutaneous sclerosis), to inflammation of connective tissue (fibrosis), and then muscle and joint 
tightening (joint contracture). The incidence, risk factors, and transplant outcomes of sclerotic GVHD 
in HCT recipients had not been extensively examined until a recent study published in the 
journal Blood by Dr. Yoshihiro Inamoto (postdoctoral fellow in the Long-Term Follow Up Program), 
Dr. Mary Flowers (senior author), and colleagues from the Clinical Research Division. 
The researchers examined a cohort of 977 HCT recipients that were treated with 
immunosuppressive drugs for chronic GVHD from May 2000 to December 2009. At initial treatment, 
7% of patients presented with sclerosis, and the cumulative incidence of sclerosis reached 20% 
within 3 years after initial treatment of GVHD (95% CI, 17.5%-22.5%). Previous smaller studies had 
reported a sclerotic GVHD incidence of 10% to 15%. "This result is important to alert hematologists 
and oncologists who may not be familiar with this complication, and will help to counsel patients 
about this complication when considering an allogeneic transplant and, after transplant, when they 
develop chronic GVHD," according to Drs. Flowers and Inamoto. 
 Using multivariate analysis, the investigators identified two factors that increase the risk of 
developing sclerosis: the use of mobilized blood stem cells for the graft (hazard ratio [HR] 1.99; 95% 
CI, 1.20-3.31; P = 0.008), and total body irradiation greater than 450 centigray when preparing 
patients for transplant (HR 1.62; 95% CI, 1.14-2.31; P = 0.008). Mobilized blood stem cell transplant 
increases the risk of developing chronic GVHD overall. The cytokine treatment used to mobilize  
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stem cells from the bone marrow to the blood stream was previously shown to cause a certain type 
of T cell differentiation that contributes to sclerotic GVHD in murine transplant models. The 
researchers speculate that irradiation of skin could also contribute to sclerosis through increased 
presentation of sclerotic antigens to donor T cells through epidermal damage and cytokine 
production. 
Decreased risk of sclerosis was associated with human leukocyte antigen (HLA)-mismatched donor 
(HR 0.57; 95% CI, 0.37-0.89; P = 0.01) and with the use of a major ABO-mismatched donor (HR 
0.65; 95% CI, 0.45-0.94; P = 0.02) compared to matched donors. The ABO antigens are sugars on 
red blood cells that determine blood type, and have been shown to increase risk for acute but not 
chronic GVHD, but the mechanisms remain unclear. HLA subtype determines immune cell 
recognition of self and non-self. HLA mismatch increases the risk of chronic GVHD, making the 
association with decreased risk of sclerosis surprising. The authors speculate that HLA mismatching 
may decrease the presentation of sclerotic antigens to donor T cells, thus decreasing the risk of 
sclerosis. However, the precise mechanism for the decreased risk of sclerosis with ABO and HLA 
mismatching remains unclear. 
The presence of sclerosis in chronic GVHD patients had no effect on the risk of overall mortality, 
nonrelapse mortality or malignancy relapse post-transplant. However, developing sclerosis 
increased the time patients were treated with immunosuppressive drugs, which can increase the risk 
of infections and other complications in transplant survivors. While sclerotic GVHD does not affect 
the prognosis of HCT recipients, sclerosis can cause pain and disability in patients. 
"Our findings will help to identify candidates for early interventional studies aimed to reduce disability 
related to sclerosis," according to Drs. Flowers and Inamoto, and "will foster future studies exploring 
pathogenic mechanisms of sclerosis, genetic risk factors for sclerosis, and proteomic profile 
associated with sclerosis." 
 
Inamoto Y, Storer BE, Petersdorf EW, Nelson JL, Lee SJ, Carpenter PA, Sandmaier BM, Hansen 
JA, Martin PJ, Flowers ME. 2013. Incidence, risk factors and outcomes of sclerosis in patients with 
chronic graft-versus-host disease. Blood. Epub ahead of print, doi: 10.1182/blood-2012-10-464198 
 
 
May 20, 2013 SCIENCE SPOTLIGHT 
 
3 Volume 3, Issue 5 | Fred Hutchinson Cancer Research Center 
 
 
 
Images provided by Yoshiro Inamoto and Mary Flowers 
Clinical and histological manifestations of sclerotic chronic graft-
versus-host disease (GVHD): dimpling signs with erythema in 
the arm (top), histological findings (left), limited range of motion 
associated with fasciitis (middle), and sclerosis and ulcers in the 
legs (right). 
 
